SANOFI SAYS CO, GSK INTEND TO MAKE AVAILABLE 200 MLN DOSES OF ADJUVANTED RECOMBINANT PROTEIN-BASED COVID-19 VACCINE, IF APPROVED, TO COVAX FACILITY
Stock market news
- Stock
- Stock market news
- Economy
- Sanofi Says Co, Gsk Intend To Make Available 200 Mln Doses Of Adjuvanted Recombinant Protein-Based Covid-19 Vaccine, If Approved, To Covax Facility